Decipher Labs Ltd Stock Price Today (NSE: DECIPHER)
Fundamental Score
Decipher Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Decipher Labs Ltd share price today is ₹5.60, up +0.00% on NSE/BSE as of 22 September 2026. Decipher Labs Ltd (DECIPHER) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹7.06 (Cr). The 52-week high for DECIPHER share price is ₹11.20 and the 52-week low is ₹5.00. The company has a Return on Equity (ROE) of -14.15% and a debt-to-equity ratio of 0.02.
Decipher Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Decipher Labs Ltd share price chart: -11.58% return over the past month. 52-week high ₹11.20, 52-week low ₹5.00.
Decipher Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹5.15 | ₹5.65 | ₹5.15 | ₹5.65 | 1.19K (Cr) | |
| ₹5.32 | ₹5.65 | ₹5.32 | ₹5.65 | 1.96K (Cr) | |
| ₹5.70 | ₹5.70 | ₹5.69 | ₹5.69 | 1.42K (Cr) | |
| ₹5.51 | ₹5.70 | ₹5.51 | ₹5.70 | 2.33K (Cr) | |
| ₹5.85 | ₹5.85 | ₹5.40 | ₹5.75 | 4.05K (Cr) | |
| ₹5.88 | ₹5.88 | ₹5.85 | ₹5.85 | 2.40K (Cr) | |
| ₹5.88 | ₹5.88 | ₹5.30 | ₹5.88 | 5.01K (Cr) | |
| ₹5.90 | ₹5.91 | ₹5.88 | ₹5.88 | 2.64K (Cr) | |
| ₹5.97 | ₹6.12 | ₹5.88 | ₹5.88 | 805.00 (Cr) | |
| ₹6.30 | ₹6.30 | ₹6.00 | ₹6.00 | 6.41K (Cr) |
Decipher Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹6.90 | ₹6.90 | ₹5.15 | ₹5.65 | -18.12% | |
| ₹7.35 | ₹7.35 | ₹5.46 | ₹6.33 | -13.88% | |
| ₹7.55 | ₹7.55 | ₹6.01 | ₹6.71 | -11.13% | |
| ₹8.00 | ₹8.00 | ₹7.02 | ₹7.55 | -5.63% | |
| ₹5.16 | ₹8.25 | ₹5.16 | ₹8.00 | +55.04% | |
| ₹5.93 | ₹6.84 | ₹5.00 | ₹5.00 | -15.68% | |
| ₹8.05 | ₹8.88 | ₹7.21 | ₹7.40 | -8.07% | |
| ₹10.90 | ₹10.90 | ₹7.50 | ₹7.80 | -28.44% | |
| ₹10.58 | ₹10.60 | ₹9.00 | ₹10.45 | -1.23% | |
| ₹9.24 | ₹10.99 | ₹9.00 | ₹9.99 | +8.12% | |
| ₹10.25 | ₹10.77 | ₹9.01 | ₹9.38 | -8.49% | |
| ₹10.64 | ₹11.20 | ₹10.07 | ₹10.47 | -1.60% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Decipher Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Decipher Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DECIPHER across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (91.24%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 7.24)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-14.15%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-16.67%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-2.24%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (-24.04% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-1.69 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (16.43%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Decipher Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Decipher Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Decipher Labs LtdDecipher Labs L...Selected✓ DECIPHER • 524752 | 9.1/100 | ₹5.60₹6 | ₹7.06₹7.06 | — — | -14.15%Poor -14.15% Poor | -16.67%Poor -16.67% Poor | 0.02Excellent 0.0 Excellent | — — | -24.04%Poor -24.04% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Decipher Labs Ltd Quarterly Performance
Latest quarterly metrics for DECIPHER — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
2.86%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
91.24%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-24.04%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Decipher Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DECIPHER — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Decipher Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Decipher Labs Ltd (DECIPHER) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Decipher Labs Ltd
About DECIPHER (Decipher Labs Ltd)
Decipher Labs Ltd is a dynamic pharmaceutical company dedicated to unraveling complex health challenges through innovative drug development and strategic partnerships. With a focus... on both domestic and international markets, DECIPHER strives to deliver high-quality pharmaceutical solutions that improve patient outcomes. The company's research and development efforts are geared towards identifying novel therapeutic targets and formulating effective treatments for a wide range of diseases. DECIPHER is committed to maintaining the highest standards of quality and regulatory compliance across all its operations, from drug discovery to manufacturing and distribution. Beyond pharmaceuticals, DECIPHER also leverages its expertise in technology to offer specialized IT solutions, fostering synergy between healthcare and technological advancements. At the core of DECIPHER's operations are two key divisions: Pharmaceutical and Consultancy. The Pharmaceutical division is responsible for the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, including branded formulations, finished drugs, and essential chemical compounds. The Consultancy division provides comprehensive IT services tailored to the needs of the healthcare industry, offering technology integration, systems consulting, and software development expertise. By combining its pharmaceutical capabilities with its technological prowess, DECIPHER aims to revolutionize healthcare delivery and improve access to innovative treatments for patients worldwide. Decipher Labs Ltd is driven by a team of experienced scientists, healthcare professionals, and technology experts who are passionate about making a positive impact on global health. The company's commitment to research and development, coupled with its dedication to ethical business practices, positions it as a trusted partner in the pharmaceutical industry. DECIPHER's unwavering focus on innovation, quality, and customer satisfaction ensures that it remains at the forefront of pharmaceutical advancements, while its commitment to corporate social responsibility drives it to contribute to the well-being of communities around the world.
Company Details
Key Leadership
DECIPHER Share Price: Frequently Asked Questions
What is the current share price of Decipher Labs Ltd?
Decipher Labs Ltd (DECIPHER) trades at ₹5.60 on NSE and BSE. Market cap ₹7.06 (Cr). Educational data only.
What is the P/E ratio of Decipher Labs Ltd?
Decipher Labs Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Decipher Labs Ltd?
Decipher Labs Ltd has a Bull Run score of 9.1/100 based on 25+ financial parameters.
Does Decipher Labs Ltd pay dividends?
Decipher Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Decipher Labs Ltd?
Decipher Labs Ltd has ROE of -14.15%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Decipher Labs Ltd?
Decipher Labs Ltd has debt-to-equity of 0.02.
Is Decipher Labs Ltd a good investment?
Bull Run gives Decipher Labs Ltd a score of 9.1/100. This is not investment advice — consult a SEBI-registered advisor.